课题基金 / 基金详情

Regulation of TH17 plasticity and stemness by mTORC1

Regulation of TH17 plasticity and stemness by mTORC1
mTORC1 对 TH17 可塑性和干性的调节
批准号:
10094053
负责人:
Hongbo Chi
金额:
$44.88万
依托单位国家:
美国
项目类别:
财政年份:
2018
资助国家:
美国
项目状态:
已结题
起止时间:
2018-02-13 至 2023-01-31

项目摘要

项目成果

Hongbo Chi的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Program Description/Abstract Lineage commitment and maintenance are fundamental processes in a variety of biological systems. In the immune system, dysregulated T cell responses are the cause of many allergic and inflammatory disorders. TH17 cells play a key pathogenic role in Multiple sclerosis (MS) and its murine model, experimental autoimmune encephalomyelitis (EAE). A unique feature of TH17 cells is their inherent plasticity that endows mature effector TH17 cells with characteristics of other T cell subsets especially TH1 cells, but how this process is controlled and its functional significance remain elusive. Coordination of T cell metabolic programs with cell fate decisions is a fundamental process in adaptive immunity, but how metabolic pathways intersect with immune signals in T cell fate decisions and autoimmune dysregulation is poorly defined. In particular, the function of metabolic programs in effector T cell plasticity and pathogenicity remains essentially unexplored. We hypothesize that the inherent heterogeneity of TH17 cells underlies their lineage plasticity; the balance between terminal differentiation and sustained stemness depends upon mTORC1 signaling and metabolic reprogramming, and contributes to autoimmune inflammation. Aim 1. Determine transcriptional mechanisms and developmental trajectory underlying TH17 terminal differentiation and stemness. Aim 2. Establish the signaling and metabolic mechanisms of mTORC1 in TH17 responses. Aim 3. Establish metabolic control and signaling circuits of TH17 plasticity. There has been little description of molecular pathways regulating TH17 lineage plasticity. We argue that insight into metabolic control of TH17 plasticity could establish a new paradigm of T cell fate control mechanisms, and manifest legitimate therapeutic opportunities for autoimmune diseases.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Enabling immunotherapy for high-risk Group 3 medulloblastoma via systems immunology
Integrating systems immunology with immunometabolism and cancer immunity
Integrating systems immunology with immunometabolism and cancer immunity
2020 Immunometabolism in Health and Disease GRC
  • 批准号:
    9912281
  • 项目类别:
  • 资助金额:
    $0.6万
  • 财政年份:
    2021
  • 负责人:
    Hongbo Chi
  • 依托单位:
海外基金